Evonile Pharma Limited has designated Mr. Gagan Sharma – President Specialty Business, as a Senior Management Personnel effective from October 26, 2026. The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and includes the required annexure as per SEBI Circular No. SEBI/HO/CFD/CFD‐PoD1/P/CIR/2023/123 dated July 13, 2023.
Appointment Details
- Reason for Change: Appointment
- Date of Appointment: October 26, 2026
- Term of Appointment: Not specified in the disclosure
Profile of Mr. Gagan Sharma
Mr. Gagan Sharma is a senior pharmaceutical leader with over 30 years of extensive experience across diverse commercial functions. He brings a strong track record of driving strategic growth, leading business transformation, and building sustainable competitive advantage. He is recognized for navigating complex business environments and translating strategy into results. His specific expertise includes:
- Successfully leading high-performing teams
- Developing future leaders
- Accelerating brand performance through innovative commercial models and integrated omnichannel strategies
- Global product launches, portfolio management, brand revitalization, market shaping, and commercial excellence across specialty and established brands
Previous Role
Most recently, Mr. Sharma served as Therapy Area Head – Gene Therapy, Immunology and In-Market Brands at Novartis Healthcare Private Limited, where he was a member of the India Leadership Team.
Additional Information
- Disclosure of directorship between Directors: Not applicable
- The intimation was signed by Ms. Chandni Maru, Company Secretary and Compliance Officer (Membership no. 60291)
- Place of disclosure: Mumbai
Financial Impact
Financial impact of this appointment is not quantified in the disclosure.